Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Humble Beginnings: The Origin Story of Modern Biotechnology
Humble Beginnings: The Origin Story of Modern Biotechnology
Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment
Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment
Lilly rushed its Loxo deal to have a big reveal at JPM
Lilly rushed its Loxo deal to have a big reveal at JPM
How Immunotherapy Could Stop and Prevent Type 1 Diabetes
How Immunotherapy Could Stop and Prevent Type 1 Diabetes
Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas
Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas
5 Biopharma Trends to Watch in 2019
5 Biopharma Trends to Watch in 2019
Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory
Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory
Experts Forecast Cancer Research and Treatment Advances in 2019
Experts Forecast Cancer Research and Treatment Advances in 2019
Top 10 Cancer Research News Stories of 2018
Top 10 Cancer Research News Stories of 2018
Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials
Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials
Merck takes a back seat on CAR-T, handing assets to Intrexon
Merck takes a back seat on CAR-T, handing assets to Intrexon
Gilead deepens immuno-oncology push with Agenus deal
Gilead deepens immuno-oncology push with Agenus deal
Astellas Acquires Collaboration Partner Potenza, Adding Cancer Immunotherapy Programs
Astellas Acquires Collaboration Partner Potenza, Adding Cancer Immunotherapy Programs
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
